TEVJF Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 апр. 2024 @ 17:08):

Stats
Объем за сегодня	12.00
Средний объем	1 908.00
Рыночная капитализация	13.17B
EPS	$0.0705 ( 2023-09-29 )
Дата следующего отчета о доходах	( $0 ) 2024-05-08
Last Dividend	$0.345 ( 2017-06-05 )
Next Dividend	$0 ( N/A )
P/E	-23.50
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Fox Christine	Buy	253 968	Restricted Share Units
2023-11-20	Fox Christine	Buy	0
2023-11-15	Conway Vikki L	Buy	33 482	Restricted Share Units
2023-11-15	Bergwerk Dov	Buy	33 482	Restricted Share Units
2023-10-13	Bergwerk Dov	Sell	0	Ordinary Shares

INSIDER POWER
23.25
Last 96 transactions
Buy: 1 572 847 \| Sell: 982 807

Teva Pharmaceutical Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Teva Pharmaceutical Финансовые показатели

Annual	2023
Выручка:	$15.85B
Валовая прибыль:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2023
Выручка:	$15.85B
Валовая прибыль:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2022
Выручка:	$14.93B
Валовая прибыль:	$6.97B (46.72 %)
EPS:	$-2.19

FY	2021
Выручка:	$15.88B
Валовая прибыль:	$7.60B (47.83 %)
EPS:	$0.380

Financial Reports:

No articles found.

Teva Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Teva Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.52 - low (50.11%) | Divividend Growth Potential Score: 0.653 - No dividend growth expected in the near future

Information

First Dividend	$0.346	2014-02-24
Last Dividend	$0.345	2017-06-05
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	7	--
Total Paid Out	$2.38	--
Avg. Dividend % Per Year	0.00%	--
Score	1.85	--
Div. Sustainability Score	4.52
Div.Growth Potential Score	0.653
Div. Directional Score	2.59	--

Next Divdend (Est)
(2024-07-05)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.85

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
TXHPF	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
JDVB	Ex Dividend Knight	2023-07-27	Quarterly	0.00%
BKUT	Ex Dividend Junior	2023-06-29	Semi-Annually	0.00%
REMYY	Ex Dividend Junior	2023-09-26	Annually	0.00%
EXSR	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
WAKE	Ex Dividend Knight	2023-10-03	Quarterly	0.00%
LGRDY	Ex Dividend Knight	2023-05-31	Annually	0.00%
CHBH	Ex Dividend Knight	2023-10-12	Quarterly	0.00%
SGPYY	Ex Dividend Knight	2023-06-01	Semi-Annually	0.00%
GBLBY	Ex Dividend Junior	2023-05-11	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0374	1.500	-0.748	-1.123	[0 - 0.5]
returnOnAssetsTTM	-0.0136	1.200	-0.455	-0.546	[0 - 0.3]
returnOnEquityTTM	-0.0808	1.500	-2.01	-3.01	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.019	0.800	9.90	7.92	[1 - 3]
quickRatioTTM	0.542	0.800	-1.520	-1.216	[0.8 - 2.5]
cashRatioTTM	0.263	1.500	9.65	10.00	[0.2 - 2]
debtRatioTTM	0.464	-1.500	2.27	-3.41	[0 - 0.6]
interestCoverageTTM	0.914	1.000	-0.773	-0.773	[3 - 30]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.751	2.00	9.62	10.00	[0 - 20]
debtEquityRatioTTM	2.68	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.482	1.000	5.29	5.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0593	1.000	-0.814	-0.814	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0679	1.000	-0.734	-0.734	[0.2 - 2]
assetTurnoverTTM	0.364	0.800	-0.904	-0.723	[0.5 - 2]
Total Score				4.52

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-22.21	1.000	-2.34	0	[1 - 100]
returnOnEquityTTM	-0.0808	2.50	-1.292	-3.01	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.751	2.00	9.75	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.256	1.500	-5.04	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0863	1.000	-0.342	0	[0.1 - 0.5]
Total Score				0.653

Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.